期刊文献+

迷迭香酸药理作用及其递送系统的研究进展 被引量:1

Research progress on pharmacological effect and delivery system of rosmarinic acid
原文传递
导出
摘要 迷迭香酸是从迷迭香等植物中分离得到的一种多酚类化合物,具有显著的抗氧化、抗炎、抗微生物、抗肿瘤及神经保护等作用。然而,由于溶解度差、渗透性低、光不稳定性、体内靶向性差、代谢速率快等缺点,限制了其药理活性及临床产品开发。药物递送系统能够在改善药物的理化性质、保护药物稳定性、发挥更佳给药途径和提高生物利用度等方面具有显著优点。通过对迷迭香酸的药理作用及新型药物载体用于迷迭香酸递送的研究进展进行综述,为迷迭香酸的药物开发和临床应用提供参考。 Rosmarinic acid is a polyphenolic compound isolated from midiexiang(Rosmarinus officinalis)and other plants with significant anti-oxidant,anti-inflammatory,antibacterial,antitumor,and neuroprotective effects.However,rosmarinic acid has some disadvantages such as low solubility and permeability,photoinstability,in vivo poor targeting and fast metabolic rate,which limit its pharmacological activities and clinical drugs development.Drug delivery systems offer significant advantages in terms of improving the physicochemical properties,protecting stability,achieving better administration routes and increasing bioavailability.In this paper,the different pharmacological effects activities of rosmarinic acid were introduced,and the research progress of new carriers for the delivery of rosmarinic acid delivery systems were reviewed,which provide reference for the development and clinical application of rosmarinic acid.
作者 龙苗苗 程贤 赵振东 陈玉湘 毕良武 LONG Miao-miao;CHENG Xian;ZHAO Zhen-dong;CHEN Yu-xiang;BI Liang-wu(Institute of Chemical Industry of Forest Products CAF,Nanjing 210042,China;Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources,Nanjing Forestry University,Nanjing 210037,China;Department of Pharmacy,Wuxi Higher Health Vocational Technology School,Wuxi 214028,China)
出处 《中草药》 CAS CSCD 北大核心 2023年第11期3715-3724,共10页 Chinese Traditional and Herbal Drugs
基金 国家自然科学基金资助项目(32201512) 广西科技重大专项(AA20302021-7) 浙江省林业科技项目(2022SY07)。
关键词 迷迭香酸 药物递送系统 抗氧化 纳米载体 生物利用度 rosmarinic acid drug delivery system anti-oxidant nanocarrier bioavailability
  • 相关文献

参考文献4

二级参考文献151

  • 1姚润心,王歆烨,杨瑞瑞.迷迭香酸对脑缺血再灌注损伤保护作用的研究[J].农垦医学,2020(5):448-452. 被引量:6
  • 2Sokoloff L. Energetics of functional activation in neural tissues. Neurochem Res 1999, 24: 321-329.
  • 3Tholey G, Ledig M. Neuronal and astrocytic plasticity: metabolic aspects. Ann Med Interne (Paris) 1990, 141 Suppl 1: 13-18.
  • 4Pratico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 2008, 29: 609-615.
  • 5Nunomura A, Castellani R J, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006, 65: 631-641.
  • 6Pocernich C, Butterfield D. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 2012, 1822(5): 625-630.
  • 7Behl C, Moosmann B. Antioxidant neuroprotection in AIzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med 2002, 15;33(2):182-191.
  • 8Moosmann B, Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs 2002, 11(10): 1407-1435.
  • 9Torres LL, Quaglio NB, de Souza GT, Garcia RT, Dati LM, Moreira WL, et al. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2011, 26: 59-68.
  • 10Beal MF. Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2005, 26: 585-586.

共引文献99

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部